Device Classification under Schedule 1 of the Medical Devices Regulations

1. Key takeaways

The Canadian device classification rules are set out in Schedule 1 of the Medical Devices Regulations and apply by virtue of section 6. Schedule 1 is divided into two parts: Part 1 contains the classification rules for non-IVD devices, including the rules for invasive devices and the rules for non-invasive devices, and Part 2 contains the classification rules for in vitro diagnostic devices. The outcome of classification is Class I, II, III, or IV, and that outcome drives the licence path, the quality system requirement, and the fee level.

• Section 6 directs users to Schedule 1, and the Schedule is the sole source of classification rules.
• Part 1 covers invasive and non-invasive devices; Part 2 covers IVDs, and the two parts are not mixed.
• A period of at least 30 consecutive days is a recurring threshold that elevates several devices to Class III.
• The classification conclusion determines three downstream matters at once: whether an MDL is needed, whether an MDSAP certificate is needed, and the fee tier.

2. Legal basis

The table below summarizes the classification provisions relied upon in this article, drawn from Schedule 1 of the Medical Devices Regulations.

3. Expert insights

Insight one: 30 consecutive days is a high-frequency threshold in the classification rules.

Both rule 1(3) and rule 2(3) use the condition that a device usually remains in the body, within a body canal, or in contact with the surface of the eye for at least 30 consecutive days as the trigger for elevation to Class III. The determination should be made on the basis of the intended duration of use stated for the product, not on the basis of how long individual patients happen to use it in practice. A label that understates the realistic duration of use will produce a class that the product cannot support, so the labelled claim and the classification determination must be consistent with each other from the start.

Insight two: even a risk-reduction claim under the same invasive route can elevate the classification.

Rule 2(4) provides that an invasive device, in respect of a body canal, that is represented for preventing sexually transmitted infection or reducing the risk of its transmission is classified as Class III. This is the classic provision in which the claim changes the class: two devices may be technically identical in form, yet a difference in the claims made for them produces a different classification. Marketing and regulatory teams must therefore review the intended-use claims together with the classification, because a claim edit alone can move the product a full class.

Insight three: rule 3 is an enumeration-first provision.

Rule 3 opens with the words Despite rules 1 and 2, and it sets denture materials and orthodontic appliances and their accessories at Class II, surgical or dental instruments at Class I, and latex condoms at Class II. This group of enumerated determinations takes precedence over the outcomes that rules 1 and 2 would otherwise suggest. The lesson for any classification exercise is that the specific enumerated rules must be checked before relying on a general rule analysis, because the enumerated rule controls even when the general analysis points the other way.

Insight four: the classification conclusion decides three subsequent matters.

The classification outcome directly determines, first, whether an MDL is required, since Class I devices do not need one; second, whether an MDSAP certificate is required, since Class II to Class IV manufacturers need one; and third, the fee tier of the application, namely 643, 14,163, or 30,713 Canadian dollars according to class. An error in classification therefore cascades: the pathway, the cost, and the timeline all need to be reworked once the class is corrected, which is why the classification step deserves independent verification before downstream work begins.

4. Practical recommendations

• Work through three steps in order, invasive versus non-invasive, then the applicable rule, then the exception provisions, and leave a written record at each step.
• For products that touch the at-least-30-consecutive-days threshold, use the labelled intended duration of use as the basis of the determination.
• Check whether an enumeration-first provision in the style of rule 3 overrides the presumptive outcome of the general rules.
• Review the classification conclusion together with the intended-use claims, so that a change in claims cannot silently elevate the classification.
• Apply the Part 2 rules of Schedule 1 to IVD products and never mix them with the Part 1 rules.

5. Verification checklist

• □ It has been determined whether Schedule 1 Part 1 or Part 2 applies
• □ The specific rule number has been located through the invasive or non-invasive analysis
• □ It has been checked whether an enumeration-first provision overrides the presumptive outcome
• □ For products with the 30 consecutive days threshold, the determination is based on the labelled duration
• □ The classification conclusion and the intended-use claims have been reviewed together
• □ The classification conclusion is documented in writing as the input to the three downstream matters: MDL, MDSAP, and fees

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com